IRC
PTCT icon

Investors Research Corp’s PTC Therapeutics PTCT Stock Holding History

Investors Research Corp’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4
Closed – – 1135
2022
Q1 		$0 Hold
4
– – ﹤0.01% 1078
2021
Q4 		$0 Buy
+4
New +$153 ﹤0.01% 1031

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Investors Research Corp's PTCT Position: Q2 2022 in Review

Investors Research Corp sold out of PTC Therapeutics (PTCT) in Q2 2022, closing a stake of 4 shares.

Investors Research Corp first reported a position in PTCT in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 180 funds tracked by Wall St. Rank hold PTCT as of Q2 2022.

  • Investors Research Corp reported no remaining PTC Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Investors Research Corp sold 4 PTC Therapeutics shares in Q2 2022.
  • Investors Research Corp first reported a position in PTC Therapeutics in Q4 2021 and held it in 2 quarters.
  • Investors Research Corp's PTC Therapeutics position peaked at $0 in Q1 2022.
  • 180 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2022.

Based on Investors Research Corp's 13F filing for Q2 2022, filed 21 Jul 2022.